In this Coronavirus Special Edition Series, we’ve talked a lot about the clinical implications of the COVID-19 pandemic. But what is the impact on the commercial side? Specifically, how are payers – key players in getting patients access to therapies – continuing to conduct business, and how are current conditions affecting priorities, if at all? Syneos Health advertising firm GSW conducted a survey to find out.
In this episode in our Coronavirus Special Edition Series, Adrian Garcia, Senior Vice President, Head of Payer & Integrated Health and Katherine Seay, Executive Vice President, Managing Director, Managed Markets at GSW, discuss the impact of the pandemic on payers, important considerations for manufacturers in engaging with these organizations in this environment, and the potential impact on formulary decision-making going into 2021.
For more information, download the full report, Payer Perspectives on Managing COVID-19.
Stay tuned for more installments of the Coronavirus Special Edition Series, which will explore, from an operational standpoint, the impact of COVID-19 on the biopharma industry, the challenges for rapid R&D in an outbreak environment, and the opportunities to leverage technology and innovation to address these critical issues. Additional materials and insights can also be found in our COVID-19 Resource Center.